Header links
Intranet
Donate now
image/svg+xml Map
Contact us

10/03/2026

Vall d'Hebron Talks 'Estudi de les seqüeles a mitjà i llarg termini de la traqueostomia percutània a la fonació, deglució i respiració'
Etiqueta
Vall d'Hebron Talks
20/03/2026

III Actualització en el diagnòstic i tractament de les malalties hepàtiques
Ubicació
Sala d'actes de l'Edifici Central del VHIR (Planta 0)
Etiqueta
Jornades
10/03/2026

Institutional Seminar Series: 'Circadian clock communication in health, ageing and disease'
Ubicació
Sala d'actes de l'Edifici Central del VHIR (Planta 0)
Etiqueta
Vall d'Hebron Talks by VHIR
17/05/2023

Vall d'Hebron Talks by VHIR 'The oncogenic role of the CDO co-receptor in Rhabdomyosarcoma: a new therapeutic target against the hedgehog pathway'
Ubicació
Sala d’actes de la planta baixa de l'edifici Collserola del VHIR
Etiqueta
Vall d'Hebron Talks by VHIR
19/05/2023

Defensa tesi 'Studies of viral and host biomarkers in hepatitis C virus infected patients'
Ubicació
Aula 114 del Mòdul Sud de la Unitat Docent de Vall d'Hebron
Etiqueta
Tesis
25/05/2023

Defensa de tesi 'Trastorns respiratoris durant el son en nens menors de 3 anys: Aspectes diferencials i avaluació dels sensors de flux aeri i d'hipoventilació en el diagnòstic'
Etiqueta
Tesis
11/01/2023

Seminari de Recerca "Extracellular vesicles secreted by triple negative breast cancer stem cells trigger pre-metastatic niche remodelling and metastatic growth in the lungs"
Ubicació
Sala d’actes de la planta baixa de l'edifici Collserola del VHIR
Etiqueta
15/11/2022

I Curs Noves Tecnologies en el Control de la Diabetis

Ubicació
Sala d’actes de la planta 10 de l’Hospital General
Etiqueta
Cursos

A 2-Part, Randomized, Double-Blind, Placebo-Controlled Study in Participants with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping with an Initial Multiple Ascending Dose Part A to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ENTR-601-45, Followed by Part B to Evaluate the Safety and Efficacy of ENTR-601-45 (ELEVATE-45)

Contact
  • Protocol code: ENTR-601-45-201
  • EudraCT code: 2024-517499-39-00
  • Pathology: Duchenne muscular dystrophy
  • Pharmac: ENTR-601-45
  • Promoter: Entrada Therapeutics, Inc.
  • Principal investigator:  Gómez Andrés, David
  • Research group:  Teràpies i Innovació en Neuropediatria i altres malalties rares pediàtriques.
  • Service: Neurologia pediàtrica
  • Phase: Fase I
  • Recruiting: Open
  • Status: Activo

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

An Open-Label Extension Study of EryDex in Patients with Ataxia Telangiectasia Following Participation in Study IEDAT-04-2022 (NEAT)

Contact
  • Protocol code: IEDAT-05-2024
  • EudraCT code: 2024-513618-37-00
  • Pathology: Ataxia Telangiectasia (A-T)
  • Pharmac: EryDex
  • Promoter: Quince Therapeutics S.p.A.
  • Principal investigator:  Gómez Andrés, David
  • Research group:  Teràpies i Innovació en Neuropediatria i altres malalties rares pediàtriques.
  • Service: Neurologia pediàtrica
  • Phase: Fase III
  • Recruiting: Open
  • Status: Activo

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.
Subscribe to